Nomacopan Receives Orphan Drug Designation for Bullous Pemphigoid
The Company is currently evaluating nomacopan in an ongoing phase 2 trial in patients with bullous pemphigoid.
Bullous Pemphigoid
BIOCHIP Test May Aid in Diagnosis of Autoimmune Bullous Diseases
The BIOCHIP mosaic-based immunofluorescence test is a simple, time- and effort-saving tool that can aid in the diagnosis and screening of bullous diseases.
Risk Factors Associated With Bullous Pemphigoid in Type 2 Diabetes
Investigators sought to determine risk factors associated with the development of bullous pemphigoid.
Rituximab is Safe, Feasible for Improving Remission in Bullous Pemphigoid
Treatment with rituximab may improve remission rates, reduce the use of steroids, and be safe in patients with bullous pemphigoid.
Diffuse Bullous Skin Lesions
In Case 1, 55-year-old man presents to the clinic with multiple tense bullae diffusely involving his trunk and extremities that overlie urticarial plaques. In Case 2, 40-year-old African American man presented to the clinic with a few small flaccid blisters as well as multiple crusted erosions and some areas of post-inflammatory hyperpigmentation on his back and in the creases of his elbows.
Weak Evidence for Increased Prevalence of Bullous Pemphigoid Among Cancer Patients
Higher incidence rates of subsequent BP have been reported in patients with brain and nervous system tumors than in those with other forms of cancer.
Estimates of Pemphigoid Prevalence in the United States Based on Age and Gender
Women 60 and older comprise the majority of cases of pemphigoid in the United States.
Derm Dx: Skin Blisters and Erosion in an Elderly Woman
A 77-year-old woman is sent for consultation from a nursing home for evaluation of skin blisters and erosions. She is unable to provide meaningful history, but according to the nursing records, the condition has been present several weeks and is being treated with a topical antibiotic ointment. She is currently taking multiple oral medications for…
Bullous Pemphigoid Risk in Patients With Diabetes Treated With DPP-4 Inhibitors
The association between DPP-4 inhibitor use and the risk for developing bullous pemphigoid was examined.
Link Between Bullous Pemphigoid and Dipeptidyl Peptidase-4 Inhibitors
The relationship between bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Next post in General Dermatology
